Tesamorelin vs hexarelin compared: FDA status, mechanism, dosing, and research findings, plus how each growth hormone peptide differs in studies.
Tesamorelin and hexarelin both stimulate growth hormone release, but they belong to different peptide classes and have very different regulatory status. Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that the FDA has approved for one specific medical condition, while hexarelin is an investigational ghrelin-receptor peptide with no approved human use. The comparison is mainly about mechanism, evidence quality, and safety.
What Is Tesamorelin?
Tesamorelin is a 44-amino-acid peptide that copies the structure of natural GHRH. It binds GHRH receptors in the pituitary gland and prompts the same pulsatile growth hormone release the body produces on its own.
The FDA approved tesamorelin (sold as Egrifta and later Egrifta SV) in 2010 for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is given as a daily subcutaneous injection under medical supervision.
- Class: GHRH analog, not a GHRP
- Approved use: Visceral fat reduction in HIV-associated lipodystrophy
- Monitoring: IGF-1 levels and blood sugar are usually checked during treatment
- Research interest: Body composition and small cognitive studies in older adults
Tesamorelin is not approved for weight loss, athletic performance, or general anti-aging use in the United States.
What Is Hexarelin?
Hexarelin is a synthetic six-amino-acid peptide from the growth hormone-releasing peptide (GHRP) family. It activates the ghrelin receptor, also called GHS-R1a, and it also binds CD36, a receptor found in heart tissue and other organs.
Hexarelin has never been approved by the FDA for any indication. What exists is laboratory and animal research, plus a small number of older human studies, most of them in children with short stature or adults with specific hormone deficiencies.
- Class: GHRP and ghrelin-receptor agonist
- Approved use: None; it is sold as a research chemical only
- Notable research interest: Cardiac protection in animal models
- Known drawbacks: Rapid desensitization of the GH response and increased appetite
Hexarelin is not FDA-approved for human use in the United States.
Tesamorelin vs Hexarelin: Side-by-Side Comparison
The table below summarizes the practical differences that most people are trying to sort out.
| Feature | Tesamorelin | Hexarelin |
|---|---|---|
| Peptide class | GHRH analog | GHRP (ghrelin agonist) |
| Amino acid length | 44 amino acids | 6 amino acids |
| Primary receptor | GHRH receptor | GHS-R1a (ghrelin) plus CD36 |
| FDA approval | Approved for HIV-associated lipodystrophy | Not approved for any use |
| Reported half-life | Roughly 26-38 minutes | Short, generally under 1 hour |
| GH response pattern | Steady, sustained rise in GH and IGF-1 | Sharp acute pulse, fades with repeat use |
| Human safety data | Large clinical trial program | Limited and mostly older studies |
| Legal status in the US | Prescription only | Sold as a research chemical |
How Each Peptide Raises Growth Hormone
Tesamorelin works upstream. It mimics natural GHRH, so the pituitary releases growth hormone in a pattern closer to the body's own rhythm, and IGF-1 climbs gradually over several weeks.
Hexarelin works through a different door. Ghrelin-receptor activation produces a fast GH spike, but the pituitary becomes less responsive when the peptide is used repeatedly. That desensitization is a major reason hexarelin is studied in short protocols rather than long ones.
Because the two pathways are separate, some research protocols pair a GHRH analog with a GHRP to test whether the effects add up. Human data on those combinations remain thin.
Where Other Peptides Fit In
People comparing GHRH analogs often search sermorelin vs tesamorelin, since both target the same receptor and differ mainly in half-life and approval status. Researchers weighing GHRPs frequently review ipamorelin vs hexarelin to see how a more selective peptide changes the side effect profile.
Combination questions are common too. Searches like cjc-1295 ipamorelin vs tesamorelin, tesamorelin vs sermorelin vs cjc-1295, and tesamorelin peptide vs ipamorelin all come down to the same variables: receptor target, half-life, and how much human safety data exists. A frequent query, hexarelin vs sermorelin vs tesamorelin, usually reflects confusion between the GHRP and GHRH families.
Safety, Legal Status, and Buying Realities
Tesamorelin carries known side effects, including injection site reactions, joint and muscle pain, swelling, and changes in blood sugar. It also requires IGF-1 monitoring, and it should not be used during pregnancy or in people with active cancer.
Hexarelin's long-term human safety profile is essentially unknown. Reported effects in small studies include increased appetite, higher cortisol and prolactin in some cases, and reduced GH response with continuous use.
In the US, tesamorelin requires a prescription, and compounded versions are not FDA-approved. Hexarelin cannot legally be sold as a supplement or drug and is typically marketed as "not for human consumption," which means purity and potency are not verified by any regulator.
Anyone considering either peptide should speak with a licensed healthcare professional and get baseline bloodwork rather than relying on vendor claims or forum posts.
Bottom Line
Tesamorelin and hexarelin are not interchangeable. Tesamorelin is an FDA-approved GHRH analog with a defined medical indication and a substantial clinical trial record, and hexarelin is an unapproved research peptide with a short half-life, fast desensitization, and very limited human safety data.
For most readers, the honest answer is that hexarelin's evidence base is far weaker than tesamorelin's, and neither peptide is a general-purpose anti-aging or fat-loss solution.
Frequently Asked Questions
Is tesamorelin the same as hexarelin?
No. Tesamorelin is a 44-amino-acid GHRH analog that the FDA approved to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. Hexarelin is a six-amino-acid GHRP that activates the ghrelin receptor and is not FDA-approved for any human use. They act on different receptors and have very different amounts of clinical evidence behind them.
Which one raises growth hormone more, tesamorelin or hexarelin?
Hexarelin tends to trigger a larger, faster growth hormone spike in short-term studies, but that response fades with repeated use because of receptor desensitization. Tesamorelin produces a more gradual rise in growth hormone and IGF-1 that is maintained over months of daily use in clinical trials. Neither should be used without medical supervision.
Is hexarelin legal to buy in the United States?
Hexarelin is not an approved drug, so it cannot legally be sold as a dietary supplement or a prescription medicine in the US. It is commonly sold as a research chemical labeled "not for human consumption," and those products are not reviewed by the FDA for purity, potency, or safety. Tesamorelin, by contrast, is available only with a prescription.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.